5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: Should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma

V. Formica, A. Leary, D. Cunningham, Y. J. Chua

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

52 Citations (Scopus)

Résumé

Purpose: Capecitabine is a relatively new oral fluoropyrimidine currently licensed for the treatment of colorectal and breast cancer. Results: It has the advantage of oral administration with good tolerability and comparable activity to intravenous 5-fluorouracil. Central neurotoxicity has been described in 5-fluorouracil-treated patients but there is little data regarding capecitabine. We report here a case of reversible capecitabine-induced encephalopathy progressing to coma. Discussion: Literature on fluoropyrimidine-related neurotoxicity will also be reviewed and possible mechanisms of the drug or its metabolites crossing the blood-brain barrier will be discussed.

langue originaleAnglais
Pages (de - à)276-278
Nombre de pages3
journalCancer Chemotherapy and Pharmacology
Volume58
Numéro de publication2
Les DOIs
étatPublié - 1 août 2006
Modification externeOui

Contient cette citation